Se­ma4 shells out $623M to scoop up a lead­ing di­ag­nos­tics play­er and its trove of da­ta

Se­ma4 sees a fu­ture where pre­ci­sion med­i­cine is the stan­dard of care, and ge­net­ic test­ing is the key to get­ting there. That’s where GeneDx comes in.

The Stam­ford, CT-based AI com­pa­ny is putting down up to $623 mil­lion to buy out GeneDx, a sub­sidiary of the di­ag­nos­tics com­pa­ny OP­KO Health. Af­ter the deal clos­es next quar­ter, Se­ma4 chief Er­ic Schadt and GeneDx head Kather­ine Stue­land will team up as co-CEOs, aim­ing to serve both pa­tients and phar­ma part­ners with ma­chine learn­ing and ge­nom­ic test­ing tech­nol­o­gy.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER